Y-MABS THERAPEUTICS INC. - COMMON STOCK
12,29
14-ноября-24 10:56:36
15 мин. задержка
Акции
-0,90
-6,79%
Сегодняшний диапазон
11,50 - 12,97
ISIN
N/A
Источник
NASDAQ
- Котировки
- Графики
Новости
- Статистика
-
16 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 янв 2024 15:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
13 дек 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
13 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
31 окт 2023 06:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
18 окт 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
17 окт 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Announces Publication in Cancers
16 окт 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
21 сен 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs to Participate at Upcoming Investor Conferences in September
06 сен 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
10 авг 2023 15:05:02 Источник Nasdaq GlobeNewswire
-
Y-mAbs to Participate at Upcoming Investor Conferences
02 авг 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
01 авг 2023 15:05:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 май 2023 08:00:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
26 май 2023 08:00:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 май 2023 08:00:00 Источник Nasdaq GlobeNewswire
-
08 май 2023 15:01:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
28 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab data at AACR
18 апр 2023 08:00:02 Источник Nasdaq GlobeNewswire
-
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
05 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire